Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Philip D. Greenberg, MD, FAACR, has been elected American Association for Cancer Research president-elect for 2022-2023.He will become the association’s president at the AACR...

American Society for Transplantation and Cellular Therapy presented awards to three leaders in the fields.Society representatives presented the awards during the ASTCT Tandem Meetings...

Fumiko Chino, MD, a radiation oncologist at Memorial Sloan Kettering Cancer Center, and the first recipient of the Excellence in Equity Award at the...

Philip D. Greenberg, MD, FAACR, has been elected American Association for Cancer Research president-elect for 2022-2023.He will become the association’s president at the AACR...

Mashup Score:13

view6.workcast.net

Online Event - 1 week

Mashup Score:13

Check this box to agree to receive occasional email or other contact from the sponsor of this webinar about their programs, products, services and...

American Society for Transplantation and Cellular Therapy presented awards to three leaders in the fields.Society representatives presented the awards during the ASTCT Tandem Meetings...

Mashup Score:12

OncLive

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with...

Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier...

The ASCO Post Staff Ursula A. Matulonis, MD, on Ovarian Cancer: New Data on Mirvetuximab Soravtansine Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute,...

AZD5305, a next generation PARP inhibitor, produced favorable safety and clinical activity vs first-generation PARP inhibitors in patients with multiple different cancer...

  • 1525793163079737344 Profile photo of Madelyn

    AZD5305, a next generation PARP inhibitor, produced favorable safety and clinical activity vs first-generation PARP inhibitors in patients with multiple different cancer types. #oncology #MedTwitter https://t.co/4XxuZ1ps07 - view on twitter